Novo Nordisk A/S has a successor ready within the wings for the era of weight-loss pictures it pioneered: a capsule that helps individuals shed kilos with out the drawbacks of an injection.
The medication is the following frontier within the weight problems struggle, promising additional billions in income, and Novo is main as soon as once more. Bother is, it will possibly’t launch the drug broadly with out endangering its current best-sellers.
The capsule helps sufferers lose roughly as a lot weight because the blockbuster Wegovy. However the oral model requires way more of the identical lively ingredient, referred to as semaglutide, and Novo already can’t make sufficient of it to satisfy demand.
That leaves Novo in a bind. Both it finds a approach to additional ramp up manufacturing or it curtails the capsule’s launch, ceding floor to rivals dashing to develop competing merchandise, like Eli Lilly & Co., Amgen Inc. and Pfizer Inc.
Chief Government Officer Lars Fruergaard Jorgensen acknowledges that Novo underestimated the demand when it initially drew up plans for a capsule.
Now the corporate, which initially deliberate to use for U.S. regulatory approval final yr, has to contemplate how greatest to handle its restricted semaglutide provide.
“It’s clear that once we make a pill model and use semaglutide, we have to use lots,” Jorgensen stated in an interview on Wednesday in New York. “We can not conquer the world with that know-how as a template.”
Learn Extra: Weight-Loss Medicine Come With Severe Aspect Results, In line with a New Research
Novo has postponed a U.S. regulatory submitting to this yr and now says it would await the outcomes of extra scientific checks, together with one investigating a lower-dose model that might require much less of the lively ingredient.
At stake is the best way to keep on high of the wave of weight problems gross sales that has boosted Novo’s market worth past $530 billion, making it Europe’s high firm and a development engine for the Danish financial system. Shares of Novo rose practically 2.5% Friday, and are up 72% up to now 12 months.
Novo on Monday struck a deal to pay $11 billion for 3 factories as a part of its shareholder Novo Holdings A/S’s acquisition of Catalent Inc. Jorgensen, in a Bloomberg Tv interview, touted the transaction as a “big alternative to serve extra sufferers” in search of remedy with Wegovy and its sister drug, the diabetes shot Ozempic.
Competitors is heating up between Novo and Lilly, whose not too long ago permitted Zepbound is predicted to grow to be the best-selling drug in historical past. An experimental weight-loss capsule it’s growing moved final yr into the final stage of scientific checks.
A pill is the following milestone for a market that Bloomberg Intelligence analysts estimate will attain $80 billion by 2030. But it surely’s not the one consideration for drugmakers, who’re additionally engaged on making next-generation therapies that set off fewer negative effects, require much less frequent administration or reduce the muscle loss that may happen with speedy weight change.
Lilly’s experimental capsule is a unique sort of molecule from Novo’s that, a minimum of in concept, needs to be simpler to make and doubtlessly cheaper, stated Michael Shah, an analyst for Bloomberg Intelligence. It may also be taken with meals, he stated. In a survey, a few third of docs advised Shah and colleagues that they prescribe oral medicine earlier than pictures. Whereas injecting Wegovy with a pen isn’t as sophisticated as some would possibly suppose, “a capsule would primarily open up the market,” Shah stated.
Volunteers taking the Novo capsule alongside weight-reduction plan and train counseling misplaced about 17% of their physique weight over 68 weeks in check outcomes launched final yr. The medication contained 50 milligrams of semaglutide, about 20 instances as a lot as within the strongest dose of the weekly Wegovy injection.
Novo already sells a capsule for diabetes below the title Rybelsus that makes use of much less semaglutide than its experimental one — although nonetheless greater than the pictures — and whose annual income is a few fifth of Ozempic’s.
The Danish firm has different capsules in growth. They embody a drug acquired final yr within the buy of Inversago Pharma, which Jorgensen stated may most likely be made in a lot bigger portions. One other early-stage one works in an identical approach to CagriSema, Novo’s experimental next-generation shot.
Totally different wants
Whereas the drugmaker is continuing on all these fronts, Jorgensen stated that Novo might not must promote an weight problems capsule broadly to remain aggressive.
Japan is an instance of a market the place a pill is essential, he stated, as a result of solely specialists prescribe injected remedy. Novo has separate research to check its capsule in Asian sufferers. And within the US, he allowed, a every day capsule might be a most well-liked possibility for some. However changing your entire market, with a whole lot of hundreds of thousands of potential sufferers, is not going to be attainable, the CEO stated. The drugmaker’s market surveys counsel it isn’t needed.
“The bulk would say, ‘Properly, I would like a pill,’” Jorgensen stated. “However when you give them the choice of a weekly injection with the efficacy that semaglutide is bringing, that may be very enticing.”